Biotech News

Indivior to Report Second Quarter 2026 Financial Results and Host Webcast

Indivior (INDV)IndiviorEarnings

Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.

Access to the Live Webcast Presentation :

The webcast event and materials can be accessed on the “Investors” section of the company’s website at www.indivior.com before the event begins.

Live webcast link: https://edge.media-server.com/mmc/p/yoi9z435

Participants may access the presentation telephonically by registering with the following link:

https://register-conf.media-server.com/register/BI13430f5332af466c963ac5c255f202e0

( Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)

A replay of the presentation will be available at www.indivior.com .

About Indivior As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior .

For Further Information

Investors: Jason Thompson Indivior Tel: 804-402-7123 E-mail: jason.thompson@indivior.com

Media: Cassie France-Kelly Indivior Tel: 804-594-0836 E-Mail: Indiviormediacontacts@indivior.com

Related news

Indivior

Addiction Medicine Indivior develops and commercializes medicines for substance-use disorders. Its strategy emphasizes long-acting formulations that support sustained treatment while reducing the burden and diversion risks associated with daily medication. SUBLOCADE Franchise SUBLOCADE is a monthly extended-release buprenorphine...

Recent company news

Stock data

Close
38.67 USD
Market cap
3.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States